Clinical Trial Update: The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018) [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated MK0724 IV for improvement of neurological damage and recovery after middle cerebral artery ischemic stroke, and the study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• MK0724 IV

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Middle Cerebral Artery Stroke | Phase 2 | Status: TERMINATED